Literature DB >> 29947246

Barriers to achieving the first 90%: gender norms and HIV testing among men in the Democratic Republic of the Congo.

Geeta Nanda1, Leila Dal Santo1, Joel Nkiama Konde2, Berengere de Negri1.   

Abstract

Gender inequality and gender norms are key social drivers of the HIV epidemic through their influences on sexual relationships, behavior, and risk taking. However, few empirical studies have measured the influence of gender norms on HIV sexual-risk behaviors and HIV testing among men in sub-Saharan Africa. We analyzed cross-sectional, survey data from 399 sexually active men (ages 18-39) in Democratic Republic of the Congo to examine the relationship between the men's support for inequitable gender norms and their HIV-risk behaviors. Logistic regression analyses revealed that moderate and strong levels of support for inequitable gender norms were significantly associated with never having been tested for HIV (AOR = 2.92, p < .05 and AOR = 3.41, p < .01, for moderate and strong support, respectively). Our findings indicate that changing the prevailing gender norms should be prioritized in HIV-prevention efforts that aim to increase counseling and testing for men.

Entities:  

Keywords:  Democratic Republic of the Congo; Gender norms; HIV; men; testing

Mesh:

Year:  2018        PMID: 29947246     DOI: 10.1080/09540121.2018.1489100

Source DB:  PubMed          Journal:  AIDS Care        ISSN: 0954-0121


  2 in total

1.  The Intersection of Inequitable Gender Norm Endorsement and HIV Stigma: Implications for HIV Care Engagement for Men in Ugandan Fishing Communities.

Authors:  K M Sileo; R K Wanyenze; B Mukasa; W Musoke; S M Kiene
Journal:  AIDS Behav       Date:  2021-02-10

2.  High risk sexual behaviours associated with traditional beliefs about gender roles among men interested in medical male circumcision in South Africa.

Authors:  Candice M Chetty-Makkan; Jonathan M Grund; Evans Muchiri; Matt A Price; Mary H Latka; Salome Charalambous
Journal:  AIDS Res Ther       Date:  2021-06-22       Impact factor: 2.250

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.